

Ind-Swift Laboratories Ltd.



Ind-Swift
Care for life

Active Pharmaceutical Ingredients

Therapeutic Category

Product Name

Macrolide Antibiotic

Clarithromycin**
Clarithromycin Coated Granules*
Clarithromycin Citrate*

Cardiovascular

Atorvastatin Calcium Crystalline**
Atorvastatin Calcium Amorphous
Clopidogrel Hydrogen Sulphate-II**
Clopidogrel HCl
Ezetimibe*
Ivabradine HCl*
Ivabradine Oxalate*
Ranolazine

Antihistamine

Fexofenadine HCl**

Antidiabetic

Pioglitazone HCl*
Nateglinide* (Form B & H)
^ Saxagliptin Monohydrate
^ Sitagliptin Phosphate*

Antipsychotic

Quetiapine Fumarate**
Aripiprazole

Bone Resorption Inhibitor

Risedronate Sodium**

Parkinson's Disease

Ropinirole HCl**

Hyperparathyroidism

Cinacalcet HCl*

Analgesic (Controlled Substances)

Pentazocine Base / HCl

Aromatase Inhibitor

Letrozole**
Anastrozole**

Nootropic

Donepezil HCl** (Form I)
Donepezil HCl* (Form III)
Donepezil Base

Antidiarrhoeal / Antiprotozoal

Nitazoxanide

Alcohol Abstinence

Acamprosate Calcium**

Antineoplastic

Temozolomide*
Imatinib Mesylate* (Form Alpha & Beta)

ADHD symptoms

^ Lisdexamfetamine Dimesylate

Anticancer

^ Ibrutinib
^ Pazopanib HCl

PRODUCTS UNDER DEVELOPMENT

Antimuscarinic

^ Mirabegron

Hypercholesterolemia

^ Bempedoic Acid

Antimigraine

^ Lasmiditan

Thrombocytopenia

^ Eltrombopag Olamine

Global Accreditations



EU GMP



KOREA
FOOD & DRUG
ADMINISTRATION



Agence nationale de sécurité du médicament
et des produits de santé

Contacts

US/Canada

vikas.narendra@indswiftlabs.com

Europe & ROW

anurag.chaturvedi@indswiftlabs.com

Southeast Asia & India

vishal.vasudeva@indswiftlabs.com

Marketing office

No. 3 H (Part 1), 3rd Floor, Uppal Plaza M6,
District Centre, Jasola, New Delhi – 110025, India
T: +91-11-47051214, 47051226, 47051291

US Operations

Ind-Swift Laboratories Inc
3500 South Dupont Highway, Dover DE 19901
T: +1-908-4211234 | F: +1-908-3251613

www.indswiftlabs.com

info@indswiftlabs.com

* DMF in CTD format

**Certificate of Suitability+DMF-CTD

^ Products under R&D and offered only for
development purpose

"Products subject to patent protection are not
offered or supplied for commercial purposes
in countries where this constitutes an
infringement of patent rights".

"Products under patent protection are only
available pursuant to Section 107-A (a) of the
Indian Patents Act, 1970."

Manufacturing Capability

3*

Manufacturing locations

*including R&D Centre

26

Blocks

700KL

Reactor capacity

Multidisciplinary skills

Synthetic Medicinal Chemistry
cGMP Manufacturing

Custom Synthesis
Analytical Development

Process R&D
Regulatory Support

Dera Bassi

- Facility spread across 33 acre of land.
- 22 cGMP manufacturing blocks.
- Containment facility catering to high potency drugs.
- Dedicated facility for oncology products with worldclass isolators.

Jammu

- Facility spread across 8 acre of land.
- 4 GMP manufacturing blocks.

712

Production (tonnes)

710+

Sales volume (tonnes)



Sustainability, Our Driving Force

- We believe that sustainability is when profitability and responsibilities go together.
- Our Sustainability model is 3-D, that focuses on sustainable development of Society, Environment and Human Resource.

Dera Bassi site awarded

- Bronze certification by ECOVADIS- The world's most Trusted Business Sustainability Ratings.

Regulatory Compliance

Regulatory body	Country/Region	Products	# Successful Inspections	Last Approval Date
	US	• Approval for all 15 products for which DMF was filed	✓✓✓✓✓✓	2020
	Japan	• Risedronate sodium, Pioglitazone HCl, Trityl Olmesartan Medoxomil (intermediate)	✓✓	2018
	Europe	• Clarithromycin, Clopidogrel	✓	2016
	Germany	• Atorvastatin, Clopidogrel, Aripiprazole	✓✓	2011
	Korea	• Risedronate sodium, Ezetimibe	✓	2010
	Australia	• Clarithromycin, Donepezil, Letrozole, Ropinirole, Acamprosate, Aripiprazole, Pioglitazone, Atorvastatin	✓✓	2013
	Hungary	• Anastrozole	✓	2007
	Greece	• Clarithromycin, Clarithromycin coated granules (CCG)	✓✓	2015
	Brazil	• Clarithromycin	✓	2015
	Jordan	• Clarithromycin coated granules	✓	2019
	Mexico	• Dutasteride, Quetiapine Fumarate, Atorvastatin, Aripiprazole, Clopidogrel, Fexofenadine, Risedronate sodium	✓	2015
	Slovenia	• Clopidogrel, Imatinib mesylate, Clarithromycin, Clarithromycin granules (CCG)	✓	2019
	Ukraine	• Clopidogrel, Letrozole, Atorvastatin	Registered	-
	Russia	• Clarithromycin, Fexofenadine HCl	Registered	-

COS/CEP

Sr. No.	Substance Number	Substance	Certificate Number	Issue Date	Status
1	1651	Clarithromycin CLRCH	R1 - CEP 2008 - 299 - Rev 01	26/11/2015	Approved
2	1651	Clarithromycin	R1 - CEP 2004 - 148 - Rev 08	04/05/2022	Approved
3	2280	Fexofenadine Hydrochloride	R1 - CEP 2008 - 226 - Rev 02	09/08/2019	Approved
4	2406	Anastrozole	R1 - CEP 2013 - 140 - Rev 00	09/08/2019	Approved
5	2572	Risedronate Sodium 2.5-Hydrate	R1 - CEP 2014 - 245 - Rev 00	11/02/2020	Approved
6	2531	Clopidogrel Hydrogen Sulfate Form-I	R1 - CEP 2013 - 215 - Rev 00	31/03/2020	Approved
7	2334	Letrozole	R1 - CEP 2009 - 105 - Rev.03	26/01/2021	Approved
8	1585	Acamprosate Calcium	R1 - CEP 2008 - 200 - Rev 04	15/06/2022	Approved
9	2541	Quetiapine Fumarate	R1 - CEP 2015 - 178 - Rev 00	19/07/2021	Approved
10	2604	Ropinirole Hydrochloride	R0 - CEP 2016 - 274 - Rev 02	21/03/2022	Approved
11	2191	Atorvastatin Calcium Trihydrate	R1 - CEP 2011 - 234 - Rev 04	15/12/2021	Approved
12	2191	Atorvastatin Calcium Trihydrate Process-II	R0 - CEP 2021 - 102 - Rev 01	02/12/2021	Approved
13	2531	Clopidogrel Hydrogen Sulfate Form-II	R0 - CEP 2020 - 055 - Rev 00	12/10/2022	Approved
14	3067	Donepezil Hydrochloride Monohydrate	R0 - CEP 2021 - 116 - Rev 00	19/10/2022	Approved
15	2736	Imatinib Mesylate (Alpha Form)	2021 - 151	-	Under Review
16	2280	Fexofenadine Hydrochloride Process II	2022 - 420	-	Under Review